Lets patients with life-threatening diseases get new medicines and clinical trials faster from trusted countries.
This bill would speed up how quickly new medicines and clinical trials for immediately life-threatening diseases become available in the U.S. It would let the Food and Drug Administration (FDA) accept approvals from trusted international health agencies, rather than requiring a full, separate U.S. review. This means patients could get access to treatments sooner.
Today, drugs and clinical trials for immediately life-threatening diseases must go through a full, separate review process with the U.S. Food and Drug Administration (FDA), even if they've been approved by other trusted international health agencies. After this bill, the FDA would be able to accept approvals from specific international authorities for medicines and clinical trials for immediately life-threatening diseases, making decisions within 30 days.
HR 7953 · 119th Congress · March 17, 2026 · AI Summary by gemini-2.5-flash · 9/10
Sign in to see your representatives' phone numbers